Myeloproliferative Neoplasms News

Aaron T. Gerds, MD, MS, speaks with Healio about the challenge dosing for ruxolitinib in patients with thrombocytopenia and the development of pacritinib as a Janus kinase inhibitor “specifically for patients with low platelet counts.”

Patients with blood cancer appeared at greater risk for severe and life-threatening COVID-19 illness than healthy individuals and did not always achieve optimal protection from vaccination, according to a registry-based study in Blood.

Aaron T. Gerds, MD, MS, speaks with Healio about predictive biomarkers of week 24 transfusion independence among patients with myelofibrosis.

Aaron T. Gerds, MD, MS, speaks with Healio about results from a retrospective analysis of data from the Persist-2 study presented at ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed treatment findings from a phase two study presented at ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, reviews data from the AVID200 study that was presented at ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, highlighted findings from a study presented at ASH Annual Meeting and Exposition that explored treating advanced myelofibrosis using the LSD1 inhibitor bomedemstat.

In this video, Aaron T. Gerds, MD, MS, discusses critical takeaways from the REVEAL study presented at ASH Annual Meeting and Exposition.

Healio provided comprehensive coverage of this year’s ASH Annual Meeting and Exposition.

Direct oral anticoagulant use appeared linked to high incidence of bleeding among patients with myeloproliferative neoplasms, according to study results presented at ASH Annual Meeting & Exposition.